234 related articles for article (PubMed ID: 31490029)
21. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
Cassese S; Kufner S; Xhepa E; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
Clin Res Cardiol; 2016 Jul; 105(7):575-84. PubMed ID: 26689707
[TBL] [Abstract][Full Text] [Related]
22. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
Abdel-Wahab M; Baev R; Dieker P; Kassner G; Khattab AA; Toelg R; Sulimov D; Geist V; Richardt G
Catheter Cardiovasc Interv; 2013 Feb; 81(2):285-91. PubMed ID: 22431433
[TBL] [Abstract][Full Text] [Related]
23. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
24. Differential Prognostic Effect Between First- and Second-Generation Drug-Eluting Stents in Coronary Bifurcation Lesions: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts.
Lee JM; Hahn JY; Kang J; Park KW; Chun WJ; Rha SW; Yu CW; Jeong JO; Jeong MH; Yoon JH; Jang Y; Tahk SJ; Gwon HC; Koo BK; Kim HS
JACC Cardiovasc Interv; 2015 Aug; 8(10):1318-1331. PubMed ID: 26315734
[TBL] [Abstract][Full Text] [Related]
25. The anatomic- and clinical-based NERS (new risk stratification) score II to predict clinical outcomes after stenting unprotected left main coronary artery disease: results from a multicenter, prospective, registry study.
Chen SL; Han YL; Zhang YJ; Ye F; Liu HW; Zhang JJ; Xu B; Jiang TM; Zhou YJ; Lv SZ
JACC Cardiovasc Interv; 2013 Dec; 6(12):1233-41. PubMed ID: 24239199
[TBL] [Abstract][Full Text] [Related]
26. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations.
Magalhaes MA; Minha S; Chen F; Torguson R; Omar AF; Loh JP; Escarcega RO; Lipinski MJ; Baker NC; Kitabata H; Ota H; Suddath WO; Satler LF; Pichard AD; Waksman R
Circ Cardiovasc Interv; 2014 Dec; 7(6):768-76. PubMed ID: 25466551
[TBL] [Abstract][Full Text] [Related]
27. The DELTA 2 Registry: A Multicenter Registry Evaluating Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents in Patients With Obstructive Left Main Coronary Artery Disease.
Chieffo A; Tanaka A; Giustino G; Briede I; Sawaya FJ; Daemen J; Kawamoto H; Meliga E; D'Ascenzo F; Cerrato E; Stefanini GG; Capodanno D; Mangiameli A; Templin C; Erglis A; Morice MC; Mehran R; Van Mieghem NM; Nakamura S; De Benedictis M; Pavani M; Varbella F; Pisaniello M; Sharma SK; Tamburino C; Tchetche D; Colombo A;
JACC Cardiovasc Interv; 2017 Dec; 10(23):2401-2410. PubMed ID: 29217002
[TBL] [Abstract][Full Text] [Related]
28. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial.
Konigstein M; Ben-Yehuda O; Smits PC; Love MP; Banai S; Perlman GY; Golomb M; Ozan MO; Liu M; Leon MB; Stone GW; Kandzari DE
JACC Cardiovasc Interv; 2018 Dec; 11(24):2467-2476. PubMed ID: 30573057
[TBL] [Abstract][Full Text] [Related]
29. Long-term clinical and angiographic outcomes of percutanenous coronary intervention with everolimus-eluting stents for the treatment of cardiac allograft vasculopathy.
Cheng R; Vanichsarn C; Patel JK; Currier J; Chang DH; Kittleson MM; Makkar R; Kobashigawa JA; Azarbal B
Catheter Cardiovasc Interv; 2017 Jul; 90(1):48-55. PubMed ID: 27862865
[TBL] [Abstract][Full Text] [Related]
30. In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.
Tolerico PH; Cohen DJ; Kleiman NS; Berger PB; Brilakis ES; Piana RN; Shammo S; Keyes MJ; Kennedy KF; Massaro JM; Saucedo JF;
Catheter Cardiovasc Interv; 2012 Dec; 80(7):1127-36. PubMed ID: 22431166
[TBL] [Abstract][Full Text] [Related]
31. Comparison between drug-coated balloon angioplasty and second-generation drug-eluting stent placement for the treatment of in-stent restenosis after drug-eluting stent implantation.
Kang IS; Shehata I; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
Heart Vessels; 2016 Sep; 31(9):1405-11. PubMed ID: 26337620
[TBL] [Abstract][Full Text] [Related]
32. Percutaneous coronary intervention for acute coronary syndrome due to graft failure: use of bare-metal and drug-eluting stents and subsequent long-term clinical outcome.
Harskamp RE; Kuijt WJ; Damman P; Beijk MA; Grundeken MJ; Woudstra P; Tijssen JG; de Winter RJ
Catheter Cardiovasc Interv; 2014 Feb; 83(2):203-9. PubMed ID: 22508617
[TBL] [Abstract][Full Text] [Related]
33. Long-term clinical outcomes in patients treated with drug-eluting compared to bare-metal stents for the treatment of transplant coronary artery disease.
Lee MS; Yang T; Kandzari D; Mahmud E; Liao H; Kirtane A
Catheter Cardiovasc Interv; 2012 Oct; 80(4):533-8. PubMed ID: 21953766
[TBL] [Abstract][Full Text] [Related]
34. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
Tada T; Byrne RA; Simunovic I; King LA; Cassese S; Joner M; Fusaro M; Schneider S; Schulz S; Ibrahim T; Ott I; Massberg S; Laugwitz KL; Kastrati A
JACC Cardiovasc Interv; 2013 Dec; 6(12):1267-74. PubMed ID: 24355117
[TBL] [Abstract][Full Text] [Related]
35. Drug eluting versus bare metal stents for percutaneous coronary intervention of saphenous vein graft lesions: An updated meta-analysis of randomized controlled trials.
Ha FJ; Nogic J; Montone RA; Cameron JD; Nerlekar N; Brown AJ
Cardiovasc Revasc Med; 2018; 19(7 Pt B):837-844. PubMed ID: 29685385
[TBL] [Abstract][Full Text] [Related]
36. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
van der Heijden LC; Kok MM; Lam MK; Danse PW; Schramm AR; Jessurun GA; Tjon Joe Gin RM; van Houwelingen KG; Hautvast RW; Linssen GC; Sen H; Löwik MM; IJzerman MJ; Doggen CJ; von Birgelen C
Clin Res Cardiol; 2016 Mar; 105(3):206-15. PubMed ID: 26329584
[TBL] [Abstract][Full Text] [Related]
37. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome after percutaneous treatment of de novo coronary bifurcation lesions using first or second generation of drug-eluting stents.
Ferenc M; Buettner HJ; Gick M; Comberg T; Rothe J; Khoury F; Valina C; Toma A; Kuebler P; Riede F; Neumann FJ
Clin Res Cardiol; 2016 Mar; 105(3):230-8. PubMed ID: 26329585
[TBL] [Abstract][Full Text] [Related]
39. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
Jones DA; Rathod KS; Gallagher S; Weerackody R; Knight CJ; Rothman MT; Mathur A; Jain AK; Timmis AD; Wragg A
Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383
[TBL] [Abstract][Full Text] [Related]
40. First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial.
Grundeken MJ; Wykrzykowska JJ; Ishibashi Y; Garg S; de Vries T; Garcia-Garcia HM; Onuma Y; de Winter RJ; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; Meier B; Jüni P; Yazdani A; Copt S; Windecker S; Serruys PW
Catheter Cardiovasc Interv; 2016 Jun; 87(7):E248-60. PubMed ID: 26649651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
